Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the agreement, Pheon will develop and commercialize a next generation antibody-drug conjugate (ADC) for a wide range of hard-to-treat cancers developed using Biocytogen’s proprietary RenMiceTM platforms.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Recipient: Biocytogen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 05, 2023
Details:
The investment will enable Pheon to advance its lead ADC program PHN-010, to clinical proof-of-concept and establish a pipeline of novel ADCs. Pheon’s lead program exploits a novel target that is highly expressed in a broad range of solid tumors.
Lead Product(s): PHN-010
Therapeutic Area: Oncology Product Name: PHN-010
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Brandon Capital
Deal Size: $68.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing September 28, 2022